Description
Anti-ICOS Antibody, ADCC Enchanced (BioBet-CB-092LX) is a glycosylation-modified anti-ICOS therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ICOS antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ICOS
Full Name
Inducible T cell costimulator
Background
The protein encoded by this gene belongs to the CD28 and CTLA-4 cell-surface receptor family. It forms homodimers and plays an important role in cell-cell signaling, immune responses, and regulation of cell proliferation. [provided by RefSeq, Jul 2008]
Alternative Names
ICOS; inducible T cell costimulator
Gene ID
29851
UniProt ID
Q9Y6W8
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG4
Antibody Clone
BioBet-CB-092LX
Description
ADCC-Enhanced Anti-Human ICOS (Feladilimab) Antibody is derived from clone Feladilimab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the ICOS, and it is intended for the research of Head and neck squamous cell carcinoma .
Antibody Indication
Head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma
